Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Bögemann

Showing results (11-20 of 99) with videos related to

Pageof 10
Sort By:
Clinical Nuclear Medicine|March 20, 2019
Detection of Local Relapse of Prostate Cancer With 18F-PSMA-1007Robert Seifert, Darius Schafigh, Martin Bögemann, et al.
Cancers|March 14, 2026
Clinical Utility of PROSTest: A Prospective Study Suggesting Reduction in Unnecessary MRI and Biopsy in Men Evaluated for Prostate CancerKambiz Rahbar, Martin Bögemann, Philipp Papavasilis, et al.
Clinical Nuclear Medicine|December 7, 2016
Excellent Response to 177Lu-PSMA-617 Radioligand Therapy in a Patient With Advanced Metastatic Castration Resistant Prostate Cancer Evaluated by 68Ga-PSMA PET/CTWolfgang Roll, Axel Bode, Matthias Weckesser, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 31, 2019
A Self-Fulfilling Prophecy: Comparing <sup>177</sup>Lu-PSMA Radioligand Therapy in Taxane-Naïve Versus Posttaxane Metastasized Prostate Cancer Patients?Kambiz Rahbar, Michael S Hofman, Andres J Schrader, et al.
Clinical Nuclear Medicine|July 24, 2018
Long-term Survival and Excellent Response to Repeated 177Lu-Prostate-Specific Membrane Antigen 617 Radioligand Therapy in a Patient With Advanced Metastatic Castration-Resistant Prostate CancerWolfgang Roll, Axel Bräuer, Matthias Weckesser, et al.
Clinical Nuclear Medicine|November 8, 2016
Benefit of 68Ga-PSMA-PET/CT in Patients Considered for 223Ra-Dichloride TherapyAxel Bode, Kambiz Rahbar, Julia Konnert, et al.
Aktuelle Urologie|August 22, 2023
[Emergencies in cancer immunotherapy]Analena Handke, Thomas Hilser, Martin Bögemann, et al.
Nuklearmedizin. Nuclear Medicine|July 11, 2022
Discrepancy of PSMA PET imaging and bone scan showing limited value of bone scan and CT in evaluation of extent of bone involvementDaniel Alexander Hescheler, Lars Stegger, Katrin Schlack, et al.
Urologia Internationalis|September 29, 2020
Using Data from a Sickness Fund Claims Database to Assess the Treatment Patterns and Healthcare Resource Utilization among Patients with Metastatic Renal Cell Carcinoma in GermanyMartin Bögemann, Aleksandra Zagorska, Divine Akumo, et al.
Cancers|October 27, 2022
Time after Synthesis and Time after Injection Do Not Affect Diagnostic Quality of [<sup>18</sup>F]F-PSMA 1007 PETElisabeth Relt, Wolfgang Roll, Michael Claesener, et al.
Pageof 10

Showing results (11-20 of 99) with videos related to

Sort By:
Pageof 10
Clinical Nuclear Medicine|March 20, 2019
Detection of Local Relapse of Prostate Cancer With 18F-PSMA-1007Robert Seifert, Darius Schafigh, Martin Bögemann, et al.
Cancers|March 14, 2026
Clinical Utility of PROSTest: A Prospective Study Suggesting Reduction in Unnecessary MRI and Biopsy in Men Evaluated for Prostate CancerKambiz Rahbar, Martin Bögemann, Philipp Papavasilis, et al.
Clinical Nuclear Medicine|December 7, 2016
Excellent Response to 177Lu-PSMA-617 Radioligand Therapy in a Patient With Advanced Metastatic Castration Resistant Prostate Cancer Evaluated by 68Ga-PSMA PET/CTWolfgang Roll, Axel Bode, Matthias Weckesser, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 31, 2019
A Self-Fulfilling Prophecy: Comparing <sup>177</sup>Lu-PSMA Radioligand Therapy in Taxane-Naïve Versus Posttaxane Metastasized Prostate Cancer Patients?Kambiz Rahbar, Michael S Hofman, Andres J Schrader, et al.
Clinical Nuclear Medicine|July 24, 2018
Long-term Survival and Excellent Response to Repeated 177Lu-Prostate-Specific Membrane Antigen 617 Radioligand Therapy in a Patient With Advanced Metastatic Castration-Resistant Prostate CancerWolfgang Roll, Axel Bräuer, Matthias Weckesser, et al.
Clinical Nuclear Medicine|November 8, 2016
Benefit of 68Ga-PSMA-PET/CT in Patients Considered for 223Ra-Dichloride TherapyAxel Bode, Kambiz Rahbar, Julia Konnert, et al.
Aktuelle Urologie|August 22, 2023
[Emergencies in cancer immunotherapy]Analena Handke, Thomas Hilser, Martin Bögemann, et al.
Nuklearmedizin. Nuclear Medicine|July 11, 2022
Discrepancy of PSMA PET imaging and bone scan showing limited value of bone scan and CT in evaluation of extent of bone involvementDaniel Alexander Hescheler, Lars Stegger, Katrin Schlack, et al.
Urologia Internationalis|September 29, 2020
Using Data from a Sickness Fund Claims Database to Assess the Treatment Patterns and Healthcare Resource Utilization among Patients with Metastatic Renal Cell Carcinoma in GermanyMartin Bögemann, Aleksandra Zagorska, Divine Akumo, et al.
Cancers|October 27, 2022
Time after Synthesis and Time after Injection Do Not Affect Diagnostic Quality of [<sup>18</sup>F]F-PSMA 1007 PETElisabeth Relt, Wolfgang Roll, Michael Claesener, et al.
Pageof 10